CAR-T therapy for leukemia in children and adults
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial studies CAR-T cell therapy, a treatment that uses your own immune cells (T cells) trained to find and attack cancer cells, in people with a type of blood cancer called acute lymphoblastic leukemia (ALL) that has come back or hasn't gone away. The goal is to see how well these therapies work in both children and adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have been diagnosed with acute lymphoblastic leukemia (ALL) that has come back or has not responded to treatment, and the leukemia cells must have a marker called CD19.
- You or your child must be any age — the trial includes children and adults.
- Your doctor must have prescribed (or is considering) a CAR-T cell therapy, such as tisagenlecleucel (Kymriah), brexucabtagene autoleucel (Tecartus), or obecabtagene autoleucel, for your treatment.
- You must agree (or not object) to have your medical data collected and used for this study, following local rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
This trial tests a special immune cell treatment (CAR-T cells) for children whose leukemia or lymphoma has come back or not responded to at least two prior treatments. The goal is to see if these cells can find and destroy the cancer.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.